

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

09/896,811 06/29/2001 Thomas D. Madden 16303-008020 500 7590 09/22/2004 EXAM SEED INTELLECTUAL PROPERTY LAW GROUP PLLC KRASS, FF 701 FIFTH AVE SUITE 6300 ART UNIT	PPLICATION NO.	TORNEY DOCKET NO. CONFIRM	
SEED INTELLECTUAL PROPERTY LAW GROUP PLLC 701 FIFTH AVE SUITE 6300 ART UNIT	09/896,811	16202 00000	MATION NO. 1024
701 FIFTH AVE SUITE 6300 ART UNIT	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC		
I AKI UNII			
SEATTLE WA 00104 7000	SUITE 6300 SEATTLE, WA 98104-7092		NUMBER
3EATTLE, WA 98104-7092	DECEMBE, W	1614	

DATE MAILED: 09/22/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
' Advisory Action	09/896, 811	MADDEN ET AL.				
1	Examiner	Art Unit				
	Frederick F. Krass	1614				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence addres	s			
THE REPLY FILED 21 June 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.						
PERIOD FOR REPLY [check either a) or b)]						
a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
 1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 2. The proposed amendment(s) will not be entered because: 						
 (a) \infty they raise new issues that would require further consideration and/or search (see NOTE below); (b) \infty they raise the issue of new matter (see Note below); 						
· · · · · · · · · · · · · · · · · · ·						
(c) ☑ they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or						
(d) they present additional claims without canceling a corresponding number of finally rejected claims.						
NOTE: See Continuation Sheet.						
3. Applicant's reply has overcome the following rejection(s):						
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).						
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: <u>See Continuation Sheet</u> .						
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were n	ewly			
7. For purposes of Appeal, the proposed amendment(s explanation of how the new or amended claims wor	s) a) $oxtimes$ will not be entered or b)[uld be rejected is provided below	will be entered and or appended.	an			
The status of the claim(s) is (or will be) as follows:						
Claim(s) allowed:						
Claim(s) objected to: <u>13-15,17 and 26</u> .						
Claim(s) rejected: <u>1,2,4,5 and 17</u> .						
Claim(s) withdrawn from consideration:						
8. The drawing correction filed on is a) approved or b) disapproved by the Examiner.						
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)						
10. Other:						

Continuation Sheet (PTOL-303) 009/896,811

Application No.

Continuation of 2. NOTE: Claims 27-43 do not appear to further limit claims from which they depend, or appear to duplicate already claimed subject matter. For example, claim 37 merely repeats limitations already present in claim 1, and claim 38 duplicates subject matter already recited in claim 2. This is confusing and raises new issues of indefiniteness and duplicate claims.

Continuation of 5. does NOT place the application in condition for allowance because: The obviousness-type double patenting rejection appears to be reasonable, and no support is seen for Applicant's conclusion that the claims cannot be rendered obvious because they do not recite specific unit dosages. To the contrary, a presumption normally exists that changes in variables are not patentable where the difference is one of degree; experimentation to find workable conditions generally involves the application of no more than routine skill in the art. See for example In re Aller 105 USPQ 233. Here, the selection of appropriate dosages would apear to require the application of no more than routine skill in the art.

7 meDo